Patrik Renblad
Vermögen: 31 355 $ am 30.06.2026
Vermögen: 31 355 $ am 30.06.2026
Patrik Renblad is currently the Chief Financial Officer at Cantargia AB since 2023.
Prior to this, he was the Chief Financial Officer at SynAct Pharma AB from 2022 to 2023.
He also worked as a Finance Director-R&D at LEO Pharma A. Mr. Renblad is a graduate of the University of Lund.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CANTARGIA AB 0,06 % | 31.12.2024 | 141 405 ( 0,06 % ) | 31 355 $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CANTARGIA AB | Finanzdirektor/CFO | 15.06.2023 |
| Unternehmen | Position | Ende |
|---|---|---|
| SYNACT PHARMA AB | Finanzdirektor/CFO | 15.05.2023 |
LEO Pharma A/S
LEO Pharma A/S Medical/Nursing ServicesHealth Services Provides dermatology services | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
LEO Pharma A/S
LEO Pharma A/S Medical/Nursing ServicesHealth Services Provides dermatology services | Health Services |
University of Lund
University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cantargia AB
Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
SynAct Pharma AB
SynAct Pharma AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical drugs for treatment inflammatory diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen